Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart
disease, with complex phenotypic and genetic expression and natural history, affecting both …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often
inherited primary cardiac disease, has now transformed into a contemporary highly treatable …

Hypertrophic cardiomyopathy (HCM) is a relatively common inherited myocardial disorder,
once regarded as largely untreatable with ominous prognosis and most visibly as a common …

Background There is no established screening approach for hypertrophic cardiomyopathy
(HCM). We recently developed an artificial intelligence (AI) model for the detection of HCM …

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy
worldwide, affecting approximately 1 in 500 individuals. Current therapeutic interventions …

Summary This phase 1, randomized, double-blind, placebo-controlled study of aficamten
(formerly CK-3773274) in healthy adults identified a pharmacologically active range of …

Background People diagnosed with genetic heart diseases (GHDs) associated with sudden
cardiac death (SCD) have historically been restricted from competitive sports. Recent data …

The identification of independent risk factors for HCM-related SCD would likely contribute to
risk stratification. However, it is difficult to predict SCD with absolute certainty, as the annual …

This scientific statement from the American Heart Association focuses on treatment
strategies and modalities for cardiomyopathy (heart muscle disease) in children and serves …